Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10672107 | 0.79 | CES1 (0.54) | KMT2ANPC1RAB9ARNASEH1ALOX15 | |
| SCHEMBL14374997 | 0.78 | NOTUM (0.44) | KMT2ANPC1RAB9ARNASEH1KDM4E | |
| Diftalone SCHEMBL35351 | 0.77 | KMT2A (1.00) | KMT2ANPC1RAB9ARNASEH1ALOX15 | |
| Diftalone SCHEMBL29644941 | 0.77 | KMT2A (1.00) | KMT2ANPC1RAB9ARNASEH1ALOX15 | |
| SCHEMBL25060934 | 0.75 | HSD17B1 (0.41) | KMT2AKDM4E | |
| SCHEMBL19117596 | 0.74 | KMT2A (0.63) | KMT2ANPC1RAB9ARNASEH1ALOX15 | |
| SCHEMBL2381204 | 0.74 | KMT2A (0.63) | KMT2ANPC1RAB9ARNASEH1ALOX15 | |
| SCHEMBL22021647 | 0.74 | KMT2A (0.63) | KMT2ANPC1RAB9ARNASEH1ALOX15 | |
| SCHEMBL3169575 | 0.74 | KMT2A (0.63) | KMT2ANPC1RAB9ARNASEH1ALOX15 | |
| SCHEMBL1123547 | 0.74 | SMN1; SMN2 (0.55) | KMT2ANPC1RAB9ARNASEH1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9227517-A | — | — | None | — | — | JP | disclosed |
| US-20230226195-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| CN-113474340-A | Novel isoindolinone substituted indoles and derivatives as RAS inhibitors | 勃林格殷格翰国际有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-20210189064-A1 | POLYISOINDOLINONES, METHODS OF MANUFACTURE, AND COMPOSITIONS AND ARTICLES FORMED THEREFROM | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2021-06-24 | — | — | US | disclosed |
| EP-3443020-B1 | POLYISOINDOLINONES, METHODS OF MANUFACTURE, AND COMPOSITIONS AND ARTICLES FORMED THEREFROM | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2020-11-11 | — | — | EP | disclosed |
| EP-3443021-B1 | POLYISOINDOLINONE COMPOSITIONS, METHODS OF MANUFACTURE, AND COMPOSITIONS AND ARTICLES FORMED THEREFROM | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2020-06-03 | — | — | EP | disclosed |
| US-10640645-B2 | Polyisoindolinone compositions, methods of manufacture, and compositions and articles formed therefrom | SABIC GLOBAL TECHNOLOGIES (NL) | 2020-05-05 | — | — | US | disclosed |
| US-10544093-B2 | O-alkyl-benzylideneguanidine derivatives and therapeutic use for the treatment of disorders associated an accumulation of misfolded proteins | INFLECTIS BIOSCIENCE (FR) | 2020-01-28 | — | — | US | disclosed |
| US-20190127575-A1 | POLYISOINDOLINONE COMPOSITIONS, METHODS OF MANUFACTURE, AND COMPOSITIONS AND ARTICLES FORMED THEREFROM | SHPP GLOBAL TECHNOLOGIES B.V. (NL) | 2019-05-02 | — | — | US | disclosed |
| EP-3443021-A1 | POLYISOINDOLINONE COMPOSITIONS, METHODS OF MANUFACTURE, AND COMPOSITIONS AND ARTICLES FORMED THEREFROM | SABIC Global Technologies B.V. (NL) | 2019-02-20 | — | — | EP | disclosed |
| US-20170152220-A1 | O-ALKYL-BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF DISORDERS ASSOCIATED AN ACCUMULATION OF MISFOLDED PROTEINS | INFLECTIS BIOSCIENCE (FR) | 2017-06-01 | — | — | US | disclosed |
| WO-2008020306-A2 | ISOINDOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2006019768-A1 | HYDANTOIN DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
| EP-0409617-B1 | Process for the preparation of metal complexes of thiolactams | ZENECA LTD (GB) | 1998-11-11 | — | — | EP | disclosed |
| JP-H09227517-A | PRODUCTION OF 2-HYDROXYISOINDOL-1-ONES | KIKUKAWA YASUO | 1997-09-02 | — | — | JP | disclosed |
| US-5506253-A | REACTING ACETOXYPYRROLIDINONE COMPOUND WITH METAL TRIALKYLSILANOLATE | ZENECA LIMITED (GB) | 1996-04-09 | — | — | US | disclosed |
| US-5393750-A | Biocides | ZENECA, LIMITED (GB) | 1995-02-28 | — | — | US | disclosed |
| US-5120856-A | Bactericides, fungicides, algicides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-06-09 | — | — | US | disclosed |
| EP-0409617-A2 | Thiolactams, process for their preparation and use as biocides | ZENECA LIMITED (GB) | 1991-01-23 | — | — | EP | disclosed |
| EP-0096299-B1 | HYDROXYIMINO AND ALKOXYIMINO DERIVATIVES OF 1,4-DIHYDROPYRIDINE, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION THEREFROM | Pierrel S.p.A. (IT) | 1989-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152220-A1 | O-ALKYL-BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF DISORDERS ASSOCIATED AN ACCUMULATION OF MISFOLDED PROTEINS | HSPA5, PRNP, MAPT | KMT2A 4309/4885NPC1 391/4885RAB9A 312/4885 |
| US-10544093-B2 | O-alkyl-benzylideneguanidine derivatives and therapeutic use for the treatment of disorders associated an accumulation of misfolded proteins | HSPA5, PRNP, MAPT | KMT2A 4309/4885NPC1 391/4885RAB9A 312/4885 |
| US-20230226195-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | SNCA, ADRM1, UBE3C | KMT2A 2586/4885NPC1 1139/4885RAB9A 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.